Top

Published in:

01-12-2020 | Migraine | KEY LECTURE

Migraine neuroscience: from experimental models to target therapy

Authors: Rosaria Greco, Chiara Demartini, Roberto De Icco, Daniele Martinelli, Alessia Putortì, Cristina Tassorelli

Published in: Neurological Sciences | Special Issue 2/2020

Abstract

Migraine sciences have witnessed tremendous advances in recent years. Pre-clinical and clinical experimental models have contributed significantly to provide useful insights into the brain structures that mediate migraine attacks. These models have contributed to elucidate the role of neurotransmission pathways and to identify the role of important molecules within the complex network involved in migraine pathogenesis. The contribution and efforts of several research groups from all over the world has ultimately lead to the generation of novel therapeutic approaches, specifically targeted for the prevention of migraine attacks, the monoclonal antibodies directed against calcitonin gene-related peptide or its receptor. These drugs have been validated in randomized placebo-controlled trials and are now ready to improve the lives of a large multitude of migraine sufferers. Others are in the pipeline and will soon be available.

Andreou AP, Edvinsson L (2019) Mechanisms of migraine as a chronic evolutive condition. J Headache Pain 20(1):117PubMedPubMedCentral

Gormley P, Anttila V, Winsvold BS et al (2016) Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 48(8):856–866PubMedPubMedCentral

de Boer I, van den Maagdenberg AMJM, Terwindt GM (2019) Advance in genetics of migraine. Curr Opin Neurol 32(3):413–421PubMedPubMedCentral

Mainero C, Boshyan J, Hadjikhani N (2011) Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine. Ann Neurol 70(5):838–845PubMedPubMedCentral

Da Silva AF, Granziera C, Tuch DS, Snyder J, Vincent M, Hadjikhani N (2007) Interictal alterations of the trigeminal somatosensory pathway and periaqueductal gray matter in migraine. Neuroreport. 18(4):301–305

Maleki N, Becerra L, Nutile L, Pendse G, Brawn J, Bigal M, Burstein R, Borsook D (2011) Migraine attacks the basal ganglia. Mol Pain 7:71PubMedPubMedCentral

Coppola G, Di Lorenzo C, Schoenen J, Pierelli F (2013) Habituation and sensitization in primary headaches. J Headache Pain 14(1):65PubMedPubMedCentral

Dodick DW (2019) CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia 2019 39:445–458

Mehrotra S, Gupta S, Garrelds IM, Villalón CM, Saxena PR, Bogers AJ, Maassenvandenbrink A (2006) Effects of current and prospective antimigraine drugs on the porcine isolated meningeal artery. Naunyn Schmiedebergs Arch Pharmacol 374(3):163–175PubMed

10.

Franco-Cereceda A, Rudehill A, Lundberg JM (1987) Calcitonin gene-related peptide but not substance P mimics capsaicin-induced coronary vasodilation in the pig. Eur J Pharmacol 142(2):235–243PubMed

11.

Bouchelet I, Case B, Olivier A, Hamel E (2000) No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129(3):501–508PubMedPubMedCentral

12.

Sheykhzade M, Amandi N, Pla MV, Abdolalizadeh B, Sams A, Warfvinge K, Edvinsson L, Pickering DS (2017) Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries. Vascul Pharmacol 90:36–43PubMed

13.

Maassenvandenbrink A, Chan KY (2008) Neurovascular pharmacology of migraine. Eur J Pharmacol 585(2–3):313–319PubMed

14.

De Vries P, Villalón CM, Saxena PR (1999) Pharmacological aspects of experimental models in relation to acute antimigraine therapy. Eur J Pharmacol 375(1–3):61–74PubMed

15.

Williamson DJ, Hargreaves RJ, Hill RG, Shepheard SL (1997) Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat—intravital microscope studies. Cephalalgia 17:525–531PubMed

16.

Akerman S, Kaube H, Goadsby PJ (2004) Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 142:1354–1360PubMedPubMedCentral

17.

Akerman S, Kaube H, Goadsby PJ (2003) Vanilloid type 1 receptors (VR1) on trigeminal sensory nerve fibres play a minor role in neurogenic dural vasodilatation, and are involved in capsaicin-induced dural dilation. Br J Pharmacol 140:718–724PubMedPubMedCentral

18.

Haanes KA, Labastida-Ramírez A, Blixt FW, Rubio-Beltrán E, Dirven CM, Danser AH, Edvinsson L, MaassenVanDenBrink A (2019) Exploration of purinergic receptors aspotential anti-migraine targets using established pre-clinical migraine models. Cephalalgia 39(11):1421–1434PubMed

19.

Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J (2004) Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 43(6):697–704

20.

Connor HE, Stubbs CM, Feniuk W, Humphrey PP (1992) Effect of sumatriptan, a selective 5-HT1-like receptor agonist, on pial vessel diameter in anaesthetized cats. J Cereb Blood Flow Metab 12(3):514–519PubMed

21.

Juhl L, Petersen KA, Larsen EH, Jansen-Olesen I, Olesen J (2006) The in vivo effect of adrenomedullin on rat dural and pial arteries. Eur J Pharmacol 538(1–3):101–107PubMed

22.

Wang X, Fang Y, Liang J, Yan M, Hu R, Pan X (2014) 5-HT7 receptors are involved in neurogenic dural vasodilatation in an experimental model of migraine. J Mol Neurosci 54(2):164–170PubMed

23.

Malhotra R (2016) Understanding migraine: potential role of neurogenic inflammation. Ann Indian Acad Neurol 19(2):175–182PubMedPubMedCentral

24.

Zakharov A, Vitale C, Kilinc E, Koroleva K, Fayuk D, Shelukhina I, Naumenko N, Skorinkin A, Khazipov R, Giniatullin R (2015) Hunting for origins of migraine pain: cluster analysis of spontaneous and capsaicin-induced firing in meningeal trigeminal nerve fibers. Front Cell Neurosci 9:287PubMedPubMedCentral

25.

Knyihar-Csillik E, Tajti J, Mohtasham S, Sari G, Vecsei L (1995) Electrical stimulation of the Gasserian ganglion induces structural alterations of calcitonin gene-related peptide-immunoreactive perivascular sensory nerve terminals in the rat cerebral dura mater: a possible model of migraine headache. Neurosci Lett 184(3):189–192PubMed

26.

Limmroth V, Katsarava Z, Liedert B, Guehring H, Schmitz K, Diener HC, Michel MC (2001) An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain 92(1–2):101–106PubMed

27.

Markowitz S, Saito K, Moskowitz MA (1987) Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129–4136PubMedPubMedCentral

28.

Buzzi MG, Moskowitz MA (1990) The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202–206PubMedPubMedCentral

29.

Knyihar-Csillik E et al (1997) Effect of a serotonin agonist (sumatriptan) on the peptidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. J Neurosci Res 48(5):449–464PubMed

30.

Bohár Z, Fejes-Szabó A, Tar L, Varga H, Tajti J, Párdutz Á, Vécsei L (2013) Evaluation of c-Fos immunoreactivity in the rat brainstem nuclei relevant in migraine pathogenesis after electrical stimulation of the trigeminal ganglion. Neurol Sci 34(9):1597–1604PubMed

31.

Buzzi MG, Carter WB, Shimizu T, Heath H III, Moskowitz MA (1991) Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193–1200PubMed

32.

Zhang Q, Han X, Wu H, Zhang M, Hu G, Dong Z, Yu S (2019) Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: relevant to migraine. Mol Pain 15:1744806918820452PubMedPubMedCentral

33.

Körtési T, Tuka B, Tajti J, Bagoly T, Fülöp F, Helyes Z, Vécsei L (2018) Kynurenic acid inhibits the electrical stimulation induced elevated pituitary adenylate cyclase-activating polypeptide expression in the TNC. Front Neurol 8:745PubMedPubMedCentral

34.

Humphrey PP, Feniuk W, Perren MJ, Connor HE, Oxford AW, Coates LH, Butina D (1988) GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 94:1123–1132PubMedPubMedCentral

35.

Zagami AS, Goadsby PJ, Edvinsson L (1990) Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16(2):69–75PubMed

36.

Robert C, Bourgeais L, Arreto CD, Condes-Lara M, Noseda R, Jay T, Villanueva L (2013) Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J Neurosci 33(20):8827–8840PubMedPubMedCentral

37.

Holland PR, Akerman S, Andreou AP, Karsan N, Wemmie JA, Goadsby PJ (2012) Acid-sensing ion channel 1: a novel therapeutic target for migraine with aura. Ann Neurol 72(4):559–563PubMed

38.

Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ (1993) Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 629(1):95–102PubMed

39.

Kaube H, Hoskin KL, Goadsby PJ (1994) Acetylsalicylic acid inhibits cerebral cortical vasodilatation caused by superior sagittal sinus stimulation in the cat. Eur J Neurol 1(2):141–146PubMed

40.

Goadsby PJ, Hoskin KL (1999) Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain 82:15–22PubMed

41.

Hoskin KL, Goadsby PJ (1998) Comparison of a more and less lipophilic serotonin (5HT_1B/1D) agonist in a model of trigeminovascular nociception in cat. Exp Neurol 150:45–51PubMed

42.

Kurosawa M, Messlinger K, Pawlak M, Schmidt RF (1995) Increase of meningeal blood flow after electrical stimulation of rat dura mater encephali: mediation by calcitonin gene-related peptide. Br J Pharmacol 114:1397–1402PubMedPubMedCentral

43.

Messlinger K, Hotta H, Pawlak M, Schmidt RF (1997) Effects of the 5-HT1 receptor agonists, sumatriptan and CP 93,129, on dural arterial flow in the rat. Eur J Pharmacol 332:173–181PubMed

44.

Mitsikostas DD, Sanchez del Rio M, Waeber C, Moskowitz MA, Cutrer FM (1998) The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 76:239–248PubMed

45.

Cutrer FM, Mitsikostas DD, Ayata G, Sanchez del Rio M (1999) Attenuation by butalbital of capsaicin-induced c-fos-like immunoreactivity in trigeminal nucleus caudalis. Headache 39:697–704PubMed

46.

Mitsikostas DD, Sanchez del Rio M (2001) Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Rev 2001(35):20–35

47.

Burstein R (2001) Deconstructing migraine headache into peripheral and central sensitization. Pain 89:107–110PubMed

48.

Laborc KF, Spekker E, Bohár Z, Szűcs M, Nagy-Grócz G, Fejes-Szabó A, Vécsei L, Párdutz Á (2020) Trigeminal activation patterns evoked by chemical stimulation of the dura mater in rats. J Headache Pain 21(1):101PubMedPubMedCentral

49.

Becerra L, Bishop J, Barmettler G, Kainz V, Burstein R, Borsook D (2017) Brain network alterations in the inflammatory soup animal model of migraine. Brain Res 1660:36–46PubMedPubMedCentral

50.

Edelmayer RM, Vanderah TW, Majuta L, Zhang ET, Fioravanti B, de Felice M, Chichorro JG, Ossipov MH, King T, Lai J, Kori SH, Nelsen AC, Cannon KE, Heinricher MM, Porreca F (2009) Medullary pain facilitating neurons mediate allodynia in headache-related pain. Ann Neurol 2009(65):184–193

51.

Burgos-Vega CC, Quigley LD, Trevisan Dos Santos G, Yan F, Asiedu M, Jacobs B, Motina M, Safdar N, Yousuf H, Avona A, Price TJ, Dussor G (2019) Non-invasive dural stimulation in mice: a novel preclinical model of migraine. Cephalalgia. 39(1):123–134PubMed

52.

Boyer N, Signoret-Genest J, Artola A, Dallel R, Monconduit L (2017) Propranolol treatment prevents chronic central sensitization induced by repeated dural stimulation. Pain. 158(10):2025–2034PubMed

53.

Zhang M, Liu Y, Zhao M, Tang W, Wang X, Dong Z, Yu S (2017) Depression and anxiety behaviour in a rat model of chronic migraine. J Headache Pain 18(1):27PubMedPubMedCentral

54.

Chen N, Su W, Cui SH, Guo J, Duan JC, Li HX, He L (2019) A novel large animal model of recurrent migraine established by repeated administration of inflammatory soup into the dura mater of the rhesus monkey. Neural Regen Res 14(1):100–106PubMedPubMedCentral

55.

Ashina M, Hansen JM, Olesen J (2013) Pearls and pitfalls in human pharmacological models of migraine: 30 years’ experience. Cephalalgia 2013 33(8):540–553

56.

Demartini C, Greco R, Zanaboni AM, Sances G, De Icco R, Borsook D, Tassorelli C (2019) Nitroglycerin as a comparative experimental model of migraine pain: from animal to human and back. Prog Neurobiol 177:15–32PubMed

57.

Greco R, Mangione AS, Sandrini G, Maccarrone M, Nappi G, Tassorelli C (2011) Effects of anandamide in migraine: data from an animal model. J Headache Pain 12(2):177–183PubMedPubMedCentral

58.

Pradhan AA, Smith ML, McGuire B, Tarash I, Evans CJ, Charles A (2014) Characterization of a novel model of chronic migraine. Pain 155(2):269–274PubMed

59.

Bates EA, Nikai T, Brennan KC, Fu YH, Charles AC, Basbaum AI, Ptácek LJ, Ahn AH (2010) Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia 30(2):170–178PubMedPubMedCentral

60.

Greco R, Bandiera T, Mangione AS, Demartini C, Siani F, Nappi G, Sandrini G, Guijarro A, Armirotti A, Piomelli D, Tassorelli C (2015) Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine. Cephalalgia. 35(12):1065–1076PubMed

61.

De Icco R, Fiamingo G, Greco R, Bottiroli S, Demartini C, Zanaboni AM, Allena M, Guaschino E, Martinelli D, Putortì A, Grillo V, Sances G, Tassorelli C (2020) Neurophysiological and biomolecular effects of erenumab in chronic migraine: an open label study. Cephalalgia. 26:333102420942230

62.

Greco R, Demartini C, Zanaboni AM, Tassorelli C (2018) Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing. J Headache Pain 19(1):51PubMedPubMedCentral

63.

Tassorelli C, Greco R, Cappelletti D, Sandrini G, Nappi G (2005) Comparative analysis of the neuronal activation and cardiovascular effects of nitroglycerin, sodium nitroprusside and L-arginine. Brain Res 1051(1–2):17–24PubMed

64.

Koulchitsky S, Fischer MJ, Messlinger K (2009) Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia. 29(4):408–417PubMed

65.

Rea BJ, Wattiez AS, Waite JS, Castonguay WC, Schmidt CM, Fairbanks AM, Robertson BR, Brown CJ, Mason BN, Moldovan-Loomis MC, Garcia-Martinez LF, Poolman P, Ledolter J, Kardon RH, Sowers LP, Russo AF (2018) Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine. Pain. 159(11):2306–2317PubMedPubMedCentral

66.

De Logu F, Landini L, Janal MN et al (2019) Migraine-provoking substances evoke periorbital allodynia in mice. J Headache Pain 20(1):18PubMedPubMedCentral

67.

Mason BN, Kaiser EA, Kuburas A, Loomis MCM, Latham JA, Garcia-Martinez LF, Russo AF (2017) Induction of migraine-like photophobic behavior in mice by both peripheral and central CGRP mechanisms. J Neurosci 37(1):204–216PubMedPubMedCentral

68.

Cumberbatch MJ, Williamson DJ, Mason GS, Hill RG, Hargreaves RJ (1999) Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol 126:1478–1486PubMedPubMedCentral

69.

Levy D, Burstein R, Strassman AM (2005) Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 58:698–705PubMed

70.

Bhatt DK, Ramachandran R, Christensen SL, Gupta S, Jansen-Olesen I, Olesen J (2015) CGRP infusion in unanesthetized rats increases expression of c-Fos in the nucleus tractus solitarius and caudal ventrolateral medulla, but not in the trigeminal nucleus caudalis. Cephalalgia 35:220–233PubMed

71.

Akerman S, Goadsby PJ (2015) Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med 7(308):308ra157PubMed

72.

Pedersen SH, la Cour SH, Calloe K, Hauser F, Olesen J, Klaerke DA, Jansen-Olesen I (2019) PACAP-38 and PACAP (6-38) Degranulate rat meningeal mast cells via the orphan MrgB3-receptor. Front Cell Neurosci 13:114PubMedPubMedCentral

73.

Costa C, Tozzi A, Rainero I, Cupini LM, Calabresi P, Ayata C, Sarchielli P (2013) Cortical spreading depression as a target for anti-migraine agents. J Headache Pain 14(1):62PubMedPubMedCentral

74.

Tozzi A, de Iure A, Di Filippo M et al (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci U S A 109(46):18985–18990PubMedPubMedCentral

75.

Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L (2013) In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 481:206–217

76.

Edvinsson L, Gulbenkian S, Barroso CP, Cunha e Sá M, Polak JM, Mortensen A, Jørgensen L, Jansen-Olesen I (1998) Innervation of the human middle meningeal artery:immunohistochemistry, ultrastructure, and role of endothelium for vasomotility. Peptides 19(7):1213–1225

77.

Tfelt-Hansen P, De Vries P, Saxena PR (2000) Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 60(6):1259–1287PubMed

78.

Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J, Kane SA (2002) Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 434:49–55PubMed

79.

Sicuteri F, Del Bene E, Poggioni M, Bonazzi A (1987) Unmasking latent dysnociception in healthy subjects. Headache 27(4):180–185PubMed

80.

Sances G, Tassorelli C, Pucci E, Ghiotto N, Sandrini G, Nappi G (2004) Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia 24(2):110–119PubMed

81.

Iversen HK, Olesen J, Tfelt-Hansen P (1989) Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 38(1):17–24PubMed

82.

Ashina H, Schytz HW, Ashina M (2019) CGRP in Human Models of Migraine. Handb Exp Pharmacol 255:109–120PubMed

83.

Ashina H, Guo S, Vollesen ALH, Ashina M (2017) PACAP38 in human models of primary headaches. J Headache Pain 18(1):110PubMedPubMedCentral

84.

Falkenberg K, Rønde Bjerg H, Yamani N, Olesen J (2020) Sumatriptan does not antagonize CGRP-induced symptoms in healthy volunteers. Headache 60(4):665–676

85.

Rahmann A, Wienecke T, Hansen JM, Fahrenkrug J, Olesen J, Ashina M (2008) Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia 28:226–236PubMed

86.

Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M (2009) PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain 132:16–25PubMed

87.

Afridi S, Kaube H, Goadsby PJ (2005) Occipital activation in glyceryl trinitrate induced migraine with visual aura. J Neurol Neurosurg Psychiatry 76(8):1158–1160PubMedPubMedCentral

88.

Hansen JM, Thomsen LL, Olesen J, Ashina M (2010) Coexisting typical migraine in familial hemiplegic migraine. Neurology 74(7):594–600PubMed

89.

Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning Pv, Larsson HB, Olesen J, Ashina M (2011) Evidence for a vascular factor in migraine. Ann Neurol 69(4):635–645PubMed

90.

Christiansen I, Daugaard D, Lykke Thomsen L, Olesen J (2000) Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. Eur J Neurol 7(4):405–411PubMed

91.

Afridi SK, Kaube H, Goadsby PJ (2004) Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110(3):675–680PubMed

92.

Maniyar FH, Sprenger T, Schankin C, Goadsby PJ (2014) The origin of nausea in migraine-a PET study. J Headache Pain 15(1):84PubMedPubMedCentral

93.

Guo S, Vollesen AL, Olesen J, Ashina M (2016) Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain 157(12):2773–2781PubMed

94.

de Hoon JN, Willigers JM, Troost J, Struijker-Boudier HA, van Bortel LM (2003) Cranial and peripheral interictal vascular changes in migraine patients. Cephalalgia 23(2):96–104PubMed

95.

Di Clemente L, Coppola G, Magis D, Gérardy PY, Fumal A, De Pasqua V, Di Piero V, Schoenen J (2009) Nitroglycerin sensitises in healthy subjects CNS structures involved in migraine pathophysiology: evidence from a study of nociceptive blink reflexes and visual evoked potentials. Pain 144(1–2):156–161PubMed

96.

Perrotta A, Serrao M, Tassorelli C, Arce-Leal N, Guaschino E, Sances G, Rossi P, Bartolo M, Pierelli F, Sandrini G, Nappi G (2011) Oral nitric-oxide donor glyceryl-trinitrate induces sensitization in spinal cord pain processing in migraineurs: a double-blind, placebo-controlled, cross-over study. Eur J Pain 15(5):482–490PubMed

97.

Asghar MS, Becerra L, Larsson HB, Borsook D, Ashina M (2016) Calcitonin gene- related peptide modulates heat nociception in the human brain - an fmri study in healthy volunteers. PLoS One 11(3):e0150334

98.

Tvedskov JF, Thomsen LL, Iversen HK, Gibson A, Wiliams P, Olesen J (2004) The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia 24(7):576–585PubMed

99.

Fullerton T, Komorowski-Swiatek D, Forrest A, Gengo FM (1999) The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. J Clin Pharmacol 39(1):17–29PubMed

100.

Van der Schueren BJ, Blanchard R, Murphy MG, Palcza J, De Lepeleire I, Van Hecken A, Depré M, de Hoon JN (2011) The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol 71(5):708–717PubMedPubMedCentral

101.

Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J (2005) The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 25(2):139–147PubMed

102.

Greco R, Demartini C, Zanaboni AM, Tumelero E, Reggiani A, Misto A, Piomelli D, Tassorelli C (2020) FAAH inhibition as a preventive treatment for migraine: A pre-clinical study. Neurobiol Dis 134:104624PubMed

103.

Mogil JS, Miermeister F, Seifert F, Strasburg K, Zimmermann K, Reinold H, Austin JS, Bernardini N, Chesler EJ, Hofmann HA, Hordo C, Messlinger K, Nemmani KV, Rankin AL, Ritchie J, Siegling A, Smith SB, Sotocinal S, Vater A, Lehto SG, Klussmann S, Quirion R, Michaelis M, Devor M, Reeh PW (2005) Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci USA 102(36):12938–12943PubMed

104.

Chu DQ, Choy M, Foster P, Cao T, Brain SD (2000) A comparative study of the ability of calcitonin generelated peptide and adrenomedullin (13–52) to modulate microvascular but not thermal hyperalgesia responses. Br J Pharmacol 130(7):1589–1596PubMedPubMedCentral

105.

Marquez de Prado B, Hammond DL, Russo AF (2009) Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice. J Pain 10(9):992–1000PubMed

106.

Huang Y, Brodda-Jansen G, Lundeberg T, Yu LC (2004) Anti-nociceptive effects of calcitonin gene-related peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res 873(1):54–59

107.

Yao G, Huang Q, Wang M, Yang CL, Liu CF, Yu TM (2017) Behavioral study of a rat model of migraine induced by CGRP. Neurosci Lett 651:134–139PubMed

108.

Christensen SL, Petersen S, Kristensen DM, Olesen J, Munro G (2019) Targeting CGRP via receptor antagonism and antibody neutralisation in two distinct rodent models of migraine-like pain. Cephalalgia 39(14):1827–1837PubMed

109.

Greco R, Mangione AS, Siani F, Blandini F, Vairetti M, Nappi G, Sandrini G, Buzzi MG, Tassorelli C (2014) Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. Cephalalgia 34(8):594–604PubMed

110.

Sundrum T, Walker CS (2018) Pituitary adenylate cyclase-activating polypeptide receptors in the trigeminovascular system: implications for migraine. Br J Pharmacol 175(21):4109–4120PubMed

111.

Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF (2019) Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase- Activating Peptide. J Pharmacol Exp Ther 369(1):26–36PubMed

112.

Demartini C, Tassorelli C, Zanaboni AM, Tonsi G, Francesconi O, Nativi C, Greco R (2017) The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. J Headache Pain 18(1):94PubMedPubMedCentral

113.

Mirrasekhian E, Nilsson JLÅ, Shionoya K, Blomgren A, Zygmunt PM, Engblom D, Högestätt ED, Blomqvist A (2018) The antipyretic effect of paracetamol occurs independent of transient receptor potential ankyrin 1-mediated hypothermia and is associated with prostaglandin inhibition in the brain. FASEB J 32(10):5751–5759PubMed

114.

Vila-Pueyo M (2018) Targeted 5-HT_1F Therapies for Migraine. Neurotherapeutics 15(2):291–303

115.

Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63(5):569–611PubMed

116.

Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F (2020) Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 40(9):892–902PubMedPubMedCentral

117.

Saengjaroentham C, Strother LC, Dripps I, Sultan Jabir MR, Pradhan A, Goadsby PJ, Holland PR (2020) Differential medication overuse risk of novel anti-migraine therapeutics. Brain 143(9):2681–2688PubMed

Title: Migraine neuroscience: from experimental models to target therapy
Authors: Rosaria Greco
Chiara Demartini
Roberto De Icco
Daniele Martinelli
Alessia Putortì
Cristina Tassorelli
Publication date: 01-12-2020
Publisher: Springer International Publishing
Keywords: Migraine
Nitroglycerin
Triptan Drugs
Published in: Neurological Sciences / Issue Special Issue 2/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04808-5

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Migraine neuroscience: from experimental models to target therapy

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2020

Headache in the development of neurosciences

Mindfulness as an add-on treatment for patients with chronic migraine and medication overuse: a preliminary analysis

Erenumab efficacy in highly resistant chronic migraine: a real-life study

Migraine and rare neurological disorders

Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)

Headache in cerebral venous thrombosis